Cardiovascular Drugs Global Market Report 2022 – By Type (Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic And Anti-Anginal Drugs)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026

Cardiovascular Drugs Global Market Report 2022

Starting Price : $5000.00 $4000.00 | Pages : 300 | Published : March 2024 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

checkslacipN checkaoirsN checkscipN

The cardiovascular drugs market consists of sales of cardiovascular drugs by entities (organizations, sole traders and partnerships) that produce cardiovascular drugs to treat cardiovascular diseases. This industry includes establishments that produce anti-hypertensive drugs to prevent heart failure by controlling blood pressure and hypolipidemic drugs that reduce lipid and lipoprotein levels in the blood. It also consists of establishments which produce antithrombotic drugs to treat arterial and venous thrombosis.  

The main types of cardiovascular drugs market are anti-hypertensive drugs, hypolipidemics, anti thrombotics, and other drugs for cardiovascular diseases (congestive heart failure, anti-arrhythmic and anti-anginal drugs). Hypolipidemic drugs are a diverse class of medications used to treat high levels of fats (lipids) in the blood, such as cholesterol (hyperlipidemia). The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others.  

The global cardiovascular drugs market size is expected to grow from $146.51 billion in 2021 to $153.60 billion in 2022 at a compound annual growth rate (CAGR) of 4.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cardiovascular drugs market is expected to reach $205.71 billion in 2026 at a CAGR of 7.6%.

 

The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of cardiovascular diseases including hypertension. According to the World Health Organization, chronic disease prevalence is rose by 57% globally, in the year 2020. These factors are expected to increase the patient pool globally, thereby driving the cardiovascular drugs market during the forecast period.

 

High costs associated with drugs is a major issue faced by citizens of many countries. Pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, the pharmaceutical companies are faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of cardiovascular drugs market manufacturers.

 

NOACs are gaining wider acceptance and are replacing traditionally used anti-coagulants such as Warfarin and Heparin. Anti-coagulants have long been used in prevention of thrombus formation in patients suffering with cardiovascular diseases. Use of NOACs makes it easier for patients to continue therapy post discharge as opposed to injections of Heparin and Warfarin which need medical assistance for administration. Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb.

 

Major companies in the cardiovascular drugs market include Medtronic Inc., Boston Scientific Corporation, Abbott Laboratories, Edwards Lifesciences, Cardinal Health, Inc., Johnson & Johnson, Terumo Corporation, Getinge Group, Teleflex Inc. and Becton Dickinson.

 

North America was the largest region in the cardiovascular drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the cardiovascular drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

 

The countries covered in the cardiovascular drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam.  

 

The global cardiovascular drugs market is segmented -

1) By Type: Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs for Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic and Anti-Anginal Drugs)

 

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others  

3) By Route of Administration: Oral, Parenteral, Others

 

4) By Drug Classification: Branded Drugs, Generic Drugs  

5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

    Table Of Contents

    1. Executive Summary

    2. Report Structure

    3. Cardiovascular Drugs Market Characteristics

    3.1. Market Definition

    3.2. Key Segmentations

    4. Cardiovascular Drugs Market Product Analysis

    4.1. Leading Products/ Services

    4.2. Key Features and Differentiators

    4.3. Development Products

    5. Cardiovascular Drugs Market Supply Chain

    5.1. Supply Chain

    5.2. Distribution

    5.3. End Customers

    6. Cardiovascular Drugs Market Customer Information

    6.1. Customer Preferences

    6.2. End Use Market Size and Growth

    7. Cardiovascular Drugs Market Trends And Strategies

    8. Impact Of COVID-19 On Cardiovascular Drugs

    9. Cardiovascular Drugs Market Size And Growth

    9.1. Market Size

    9.2. Historic Market Growth, Value ($ Billion)

    9.2.1. Drivers Of The Market

    9.2.2. Restraints On The Market

    9.3. Forecast Market Growth, Value ($ Billion)

    9.3.1. Drivers Of The Market

    9.3.2. Restraints On The Market

    10. Cardiovascular Drugs Market Regional Analysis

    10.1. Global Cardiovascular Drugs Market, 2021, By Region, Value ($ Billion)

    10.2. Global Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Region

    10.3. Global Cardiovascular Drugs Market, Growth And Market Share Comparison, By Region

    11. Cardiovascular Drugs Market Segmentation

    11.1. Global Cardiovascular Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Anti-Hypertensive Drugs

    Hypolipidemics

    Anti Thrombotics

    Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic And Anti-Anginal Drugs)

    11.2. Global Cardiovascular Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies/ Drug Stores

    Others

    11.3. Global Cardiovascular Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Oral

    Parenteral

    Others

    11.4. Global Cardiovascular Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Branded Drugs

    Generic Drugs

    11.5. Global Cardiovascular Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Prescription-Based Drugs

    Over-The-Counter Drugs

    12. Cardiovascular Drugs Market Metrics

    12.1. Cardiovascular Drugs Market Size, Percentage Of GDP, 2016-2026, Global

    12.2. Per Capita Average Cardiovascular Drugs Market Expenditure, 2016-2026, Global

    13. Asia-Pacific Cardiovascular Drugs Market

    13.1. Asia-Pacific Cardiovascular Drugs Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    13.2. Asia-Pacific, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)

    13.3. Asia-Pacific, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country

    13.4. Asia-Pacific, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country

    13.5. Asia-Pacific, Cardiovascular Drugs Market Metrics

    13.5.1. Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, Asia-Pacific Countries

    13.6. Asia-Pacific Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7. Asia-Pacific Cardiovascular Drugs Market: Country Analysis

    13.7.1. China Cardiovascular Drugs Market

    13.7.1.1. China Cardiovascular Drugs Market Overview

    13.7.1.2. China Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.1.3. China Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.2. Australia Cardiovascular Drugs Market

    13.7.2.1. Australia Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.2.2. Australia Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.3. Hong Kong Cardiovascular Drugs Market

    13.7.3.1. Hong Kong Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.4. India Cardiovascular Drugs Market

    13.7.4.1. India Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.4.2. India Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.5. Indonesia Cardiovascular Drugs Market

    13.7.5.1. Indonesia Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.5.2. Indonesia Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.6. Japan Cardiovascular Drugs Market

    13.7.6.1. Japan Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.6.2. Japan Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.7. Malaysia Cardiovascular Drugs Market

    13.7.7.1. Malaysia Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.8. New Zealand Cardiovascular Drugs Market

    13.7.8.1. New Zealand Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.9. Philippines Cardiovascular Drugs Market

    13.7.9.1. Philippines Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.10. Singapore Cardiovascular Drugs Market

    13.7.10.1. Singapore Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.11. South Korea Cardiovascular Drugs Market

    13.7.11.1. South Korea Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.11.2. South Korea Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.12. Thailand Cardiovascular Drugs Market

    13.7.12.1. Thailand Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.13. Vietnam Cardiovascular Drugs Market

    13.7.13.1. Vietnam Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14. Western Europe Cardiovascular Drugs Market

    14.1. Western Europe Cardiovascular Drugs Market Overview

    14.2. Western Europe, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)

    14.3. Western Europe, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country

    14.4. Western Europe, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country

    14.5. Western Europe, Cardiovascular Drugs Market Metrics

    14.5.1. Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, Western Europe Countries

    14.6. Western Europe Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7. Western Europe Cardiovascular Drugs Market: Country Analysis

    14.7.1. Austria Cardiovascular Drugs Market

    14.7.1.1. Austria Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.2. Belgium Cardiovascular Drugs Market

    14.7.2.1. Belgium Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.3. Denmark Cardiovascular Drugs Market

    14.7.3.1. Denmark Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.4. Finland Cardiovascular Drugs Market

    14.7.4.1. Finland Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.5. France Cardiovascular Drugs Market

    14.7.5.1. France Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.5.2. France Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.6. Germany Cardiovascular Drugs Market

    14.7.6.1. Germany Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.6.2. Germany Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.7. Ireland Cardiovascular Drugs Market

    14.7.7.1. Ireland Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.8. Italy Cardiovascular Drugs Market

    14.7.8.1. Italy Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.9. Netherlands Cardiovascular Drugs Market

    14.7.9.1. Netherlands Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.10. Norway Cardiovascular Drugs Market

    14.7.10.1. Norway Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.11. Portugal Cardiovascular Drugs Market

    14.7.11.1. Portugal Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.12. Spain Cardiovascular Drugs Market

    14.7.12.1. Spain Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.13. Sweden Cardiovascular Drugs Market

    14.7.13.1. Sweden Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.14. Switzerland Cardiovascular Drugs Market

    14.7.14.1. Switzerland Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.15. UK Cardiovascular Drugs Market

    14.7.15.1. UK Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.15.2. UK Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    15. Eastern Europe Cardiovascular Drugs Market

    15.1. Eastern Europe Cardiovascular Drugs Market Overview

    15.2. Eastern Europe, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)

    15.3. Eastern Europe, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country

    15.4. Eastern Europe, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country

    15.5. Eastern Europe, Cardiovascular Drugs Market Metrics

    15.5.1. Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, Eastern Europe Countries

    15.6. Eastern Europe Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    15.7. Eastern Europe Cardiovascular Drugs Market: Country Analysis

    15.7.1. Czech Republic Cardiovascular Drugs Market,  

    15.7.1.1. Czech Republic Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    15.7.2. Poland Cardiovascular Drugs Market

    15.7.2.1. Poland Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    15.7.3. Romania Cardiovascular Drugs Market

    15.7.3.1. Romania Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    15.7.4. Russia Cardiovascular Drugs Market

    15.7.4.1. Russia Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    15.7.4.2. Russia Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    16. North America Cardiovascular Drugs Market

    16.1. North America Cardiovascular Drugs Market Overview

    16.2. North America, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)

    16.3. North America, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country

    16.4. North America, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country

    16.5. North America, Cardiovascular Drugs Market Metrics

    16.5.1. Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, North America Countries

    16.6. North America Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    16.7. North America Cardiovascular Drugs Market: Country Analysis

    16.7.1. Canada Cardiovascular Drugs Market

    16.7.1.1. Canada Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    16.7.2. Mexico Cardiovascular Drugs Market

    16.7.2.1. Mexico Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    16.7.3. USA Cardiovascular Drugs Market

    16.7.3.1. USA Cardiovascular Drugs Market Overview

    16.7.3.2. USA Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    16.7.3.3. USA Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    17. South America Cardiovascular Drugs Market

    17.1. South America Cardiovascular Drugs Market Overview

    17.2. South America, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)

    17.3. South America, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country

    17.4. South America, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country

    17.5. South America, Cardiovascular Drugs Market Metrics

    17.5.1. Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, South America Countries

    17.6. South America Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    17.7. South America Cardiovascular Drugs Market: Country Analysis

    17.7.1. Argentina Cardiovascular Drugs Market

    17.7.1.1. Argentina Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    17.7.2. Brazil Cardiovascular Drugs Market

    17.7.1.1. Brazil Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    17.7.2.2. Brazil Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    17.7.3. Chile Cardiovascular Drugs Market

    17.7.3.1. Chile Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    17.7.4. Colombia Cardiovascular Drugs Market

    17.7.4.1. Colombia Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    17.7.5. Peru Cardiovascular Drugs Market

    17.7.5.1. Peru Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    17.7.6. Venezuela Cardiovascular Drugs Market

    17.7.6.1. Venezuela Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    18. Middle East Cardiovascular Drugs Market

    18.1. Middle East Cardiovascular Drugs Market Overview

    18.2. Middle East, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)

    18.3. Middle East, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country

    18.4. Middle East, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country

    18.5. Middle East, Cardiovascular Drugs Market Metrics

    18.5.1. Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, Middle East Countries

    18.6. Middle East Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    18.7. Middle East Cardiovascular Drugs Market: Country Analysis

    18.7.1. Saudi Arabia Cardiovascular Drugs Market

    18.7.1.1. Saudi Arabia Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    18.7.2. Israel Cardiovascular Drugs Market

    18.7.2.1. Israel Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    18.7.3. Turkey Cardiovascular Drugs Market

    18.7.3.1. Turkey Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    18.7.4. UAE Cardiovascular Drugs Market

    18.7.4.1. UAE Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    19. Africa Cardiovascular Drugs Market

    19.1. Africa Cardiovascular Drugs Market Overview

    19.2. Africa, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)

    19.3. Africa, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country

    19.4. Africa, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country

    19.5. Africa, Cardiovascular Drugs Market Metrics

    19.5.1. Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, Africa Countries

    19.6. Africa Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    19.7. Africa Cardiovascular Drugs Market: Country Analysis

    19.7.1. Egypt Cardiovascular Drugs Market

    19.7.1.1. Egypt Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    19.7.2. Nigeria Cardiovascular Drugs Market

    19.7.2.1. Nigeria Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    19.7.3. South Africa Cardiovascular Drugs Market

    19.7.3.1. South Africa Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    20. Cardiovascular Drugs Market Competitive Landscape

    20.1. Competitive Market Overview

    20.2. Market Shares

    20.3. Company Profiles

    20.3.1. Medtronic Inc

    20.3.1.1. Company Overview

    20.3.1.2. Products And Services

    20.3.1.3. Strategy

    20.3.1.4. Financial Performance

    20.3.2. Boston Scientific Corporation

    20.3.2.1. Company Overview

    20.3.2.2. Products And Services

    20.3.2.3. Strategy

    20.3.2.4. Financial Performance

    20.3.3. Abbott Laboratories

    20.3.3.1. Company Overview

    20.3.3.2. Products And Services

    20.3.3.3. Strategy

    20.3.3.4. Financial Performance

    20.3.4. Edwards Lifesciences

    20.3.4.1. Company Overview

    20.3.4.2. Products And Services

    20.3.4.3. Strategy

    20.3.4.4. Financial Performance

    20.3.5. Cardinal Health, Inc

    20.3.5.1. Company Overview

    20.3.5.2. Products And Services

    20.3.5.3. Strategy

    20.3.5.4. Financial Performance

    21. Key Mergers And Acquisitions In The Cardiovascular Drugs Market

    22. Market Background: Pharmaceutical Drugs Market

    22.1. Pharmaceutical Drugs Market Characteristics

    22.2. Pharmaceutical Drugs Market Historic and Forecast, 2016-2021, 2021-2026F, 2031F Growth, By Segment, Value ($ Billion), Global

    22.3. Global Pharmaceutical Drugs Market, 2021, By Region, Value ($ Billion)

    22.4. Global Pharmaceutical Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Region

    22.5. Global Pharmaceutical Drugs Market, 2016-2021, 2021-2026F, 2031F, Segmentation By Type, Value ($ Billion)

    23. Recommendations

    23.1. Global Cardiovascular Drugs Market In 2026- Growth Countries

    23.2. Global Cardiovascular Drugs Market In 2026- Growth Segments

    23.3. Global Cardiovascular Drugs Market In 2026- Growth Strategies

    24. Appendix

    24.1. NAICS Definitions Of Industry Covered In This Report

    24.2. Abbreviations

    24.3. Currencies

    24.4. Research Inquiries

    24.5. The Business Research Company

    25. Copyright And Disclaimer

List Of Tables

    Table 1: Historic Market Growth, Value ($ Billion)
  • Table 2: Forecast Market Growth, Value ($ Billion)
  • Table 3: Global Cardiovascular Drugs Market, 2021, By Region, Value ($ Billion)
  • Table 4: Global Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Region
  • Table 5: Global Cardiovascular Drugs Market, Growth And Market Share Comparison, By Region
  • Table 6: Global Cardiovascular Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 7: Global Cardiovascular Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 8: Global Cardiovascular Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 9: Global Cardiovascular Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 10: Global Cardiovascular Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 11: Cardiovascular Drugs Market Size, Percentage Of GDP, 2016-2026, Global
  • Table 12: Per Capita Average Cardiovascular Drugs Market Expenditure, 2016-2026, Global
  • Table 13: Asia-Pacific, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 14: Asia-Pacific, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 15: Asia-Pacific, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 16: Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, Asia-Pacific Countries
  • Table 17: Asia-Pacific Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 18: China Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 19: China Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 20: Australia Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 21: Australia Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 22: Hong Kong Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 23: India Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 24: India Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 25: Indonesia Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 26: Indonesia Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 27: Japan Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 28: Japan Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 29: Malaysia Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 30: New Zealand Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 31: Philippines Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 32: Singapore Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 33: South Korea Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 34: Thailand Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 35: Vietnam Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 36: Western Europe, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 37: Western Europe, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 38: Western Europe, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 39: Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, Western Europe Countries
  • Table 40: Western Europe Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 41: Austria Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 42: Belgium Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 43: Denmark Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 44: Finland Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 45: France Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 46: France Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 47: Germany Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 48: Germany Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 49: Ireland Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 50: Italy Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 51: Netherlands Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 52: Norway Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 53: Portugal Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 54: Spain Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 55: Sweden Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 56: Switzerland Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 57: UK Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 58: UK Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 59: Eastern Europe, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 60: Eastern Europe, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 61: Eastern Europe, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 62: Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, Eastern Europe Countries
  • Table 63: Eastern Europe Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 64: Czech Republic Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 65: Poland Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 66: Romania Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 67: Russia Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 68: Russia Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 69: North America, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 70: North America, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 71: North America, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 72: Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, North America Countries
  • Table 73: North America Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 74: Canada Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 75: Mexico Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 76: USA Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 77: USA Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 78: South America, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 79: South America, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 80: South America, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 81: Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, South America Countries
  • Table 82: South America Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 83: Argentina Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 84: Brazil Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 85: Brazil Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 86: Chile Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 87: Colombia Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 88: Peru Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 89: Venezuela Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 90: Middle East, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 91: Middle East, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 92: Middle East, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 93: Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, Middle East Countries
  • Table 94: Middle East Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 95: Saudi Arabia Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 96: Israel Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 97: Turkey Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 98: UAE Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 99: Africa, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 100: Africa, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 101: Africa, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 102: Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, Africa Countries
  • Table 103: Africa Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 104: Egypt Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 105: Nigeria Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 106: South Africa Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 107: Medtronic Inc Financial Performance
  • Table 108: Boston Scientific Corporation Financial Performance
  • Table 109: Abbott Laboratories Financial Performance
  • Table 110: Edwards Lifesciences Financial Performance
  • Table 111: Cardinal Health, Inc Financial Performance
  • Table 112: Pharmaceutical Drugs Market Historic and Forecast, 2016-2021, 2021-2026F, 2031F, Growth, By Segment, Value ($ Billion), Global
  • Table 113: Global Pharmaceutical Drugs Market, 2021, By Region, Value ($ Billion)
  • Table 114: Global Pharmaceutical Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Region
  • Table 115: Global Pharmaceutical Drugs Market, 2016-2021, 2021-2026F, 2031F, Segmentation By Type, Value ($ Billion)
  • Table 116: Global Cardiovascular Drugs Market In 2026- Growth Countries
  • Table 117: Global Cardiovascular Drugs Market In 2026- Growth Segments
  • Table 118: Global Cardiovascular Drugs Market In 2026- Growth Strategies

List Of Figures

    Figure 1: Historic Market Growth, Value ($ Billion)
  • Figure 2: Forecast Market Growth, Value ($ Billion)
  • Figure 3: Global Cardiovascular Drugs Market, 2021, By Region, Value ($ Billion)
  • Figure 4: Global Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Region
  • Figure 5: Global Cardiovascular Drugs Market, Growth And Market Share Comparison, By Region
  • Figure 6: Global Cardiovascular Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 7: Global Cardiovascular Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 8: Global Cardiovascular Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 9: Global Cardiovascular Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 10: Global Cardiovascular Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 11: Cardiovascular Drugs Market Size, Percentage Of GDP, 2016-2026, Global
  • Figure 12: Per Capita Average Cardiovascular Drugs Market Expenditure, 2016-2026, Global
  • Figure 13: Asia-Pacific, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 14: Asia-Pacific, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 15: Asia-Pacific, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 16: Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, Asia-Pacific Countries
  • Figure 17: Asia-Pacific Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 18: China Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 19: China Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 20: Australia Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 21: Australia Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 22: Hong Kong Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 23: India Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 24: India Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 25: Indonesia Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 26: Indonesia Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 27: Japan Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 28: Japan Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 29: Malaysia Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 30: New Zealand Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 31: Philippines Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 32: Singapore Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 33: South Korea Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 34: Thailand Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 35: Vietnam Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 36: Western Europe, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 37: Western Europe, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 38: Western Europe, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 39: Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, Western Europe Countries
  • Figure 40: Western Europe Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 41: Austria Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 42: Belgium Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 43: Denmark Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 44: Finland Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 45: France Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 46: France Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 47: Germany Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 48: Germany Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 49: Ireland Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 50: Italy Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 51: Netherlands Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 52: Norway Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 53: Portugal Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 54: Spain Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 55: Sweden Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 56: Switzerland Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 57: UK Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 58: UK Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 59: Eastern Europe, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 60: Eastern Europe, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 61: Eastern Europe, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 62: Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, Eastern Europe Countries
  • Figure 63: Eastern Europe Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 64: Czech Republic Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 65: Poland Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 66: Romania Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 67: Russia Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 68: Russia Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 69: North America, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 70: North America, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 71: North America, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 72: Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, North America Countries
  • Figure 73: North America Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 74: Canada Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 75: Mexico Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 76: USA Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 77: USA Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 78: South America, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 79: South America, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 80: South America, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 81: Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, South America Countries
  • Figure 82: South America Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 83: Argentina Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 84: Brazil Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 85: Brazil Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 86: Chile Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 87: Colombia Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 88: Peru Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 89: Venezuela Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 90: Middle East, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 91: Middle East, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 92: Middle East, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 93: Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, Middle East Countries
  • Figure 94: Middle East Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 95: Saudi Arabia Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 96: Israel Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 97: Turkey Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 98: UAE Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 99: Africa, Cardiovascular Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 100: Africa, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 101: Africa, Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 102: Per Capita Average Cardiovascular Drugs Expenditure, 2016-2026, Africa Countries
  • Figure 103: Africa Cardiovascular Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 104: Egypt Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 105: Nigeria Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 106: South Africa Cardiovascular Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 107: Medtronic Inc Financial Performance
  • Figure 108: Boston Scientific Corporation Financial Performance
  • Figure 109: Abbott Laboratories Financial Performance
  • Figure 110: Edwards Lifesciences Financial Performance
  • Figure 111: Cardinal Health, Inc Financial Performance
  • Figure 112: Pharmaceutical Drugs Market Historic and Forecast, 2016-2021, 2021-2026F, 2031F, Growth, By Segment, Value ($ Billion), Global
  • Figure 113: Global Pharmaceutical Drugs Market, 2021, By Region, Value ($ Billion)
  • Figure 114: Global Pharmaceutical Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Region
  • Figure 115: Global Pharmaceutical Drugs Market, 2016-2021, 2021-2026F, 2031F, Segmentation By Type, Value ($ Billion)
  • Figure 116: Global Cardiovascular Drugs Market In 2026- Growth Countries
  • Figure 117: Global Cardiovascular Drugs Market In 2026- Growth Segments
  • Figure 118: Global Cardiovascular Drugs Market In 2026- Growth Strategies
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the cardiovascular drugs market?

The cardiovascular drugs market consists of sales of cardiovascular drugs by entities that produce cardiovascular drugs to treat cardiovascular diseases. This industry includes establishments that produce anti-hypertensive drugs to prevent heart failure by controlling blood pressure and hypolipidemic drugs that reduce lipid and lipoprotein levels in the blood. It also consists of establishments which produce antithrombotic drugs to treat arterial and venous thrombosis request a sample here

How will the cardiovascular drugs market drivers and restraints affect cardiovascular drugs market dynamics? What forces will shape the cardiovascular drugs industry going forward?

The cardiovascular drugs market growth is aided by rise in sedentary jobs, busy lifestyles and changing consumer preferences. However, some cardiovascular drugs market restraints include high costs associated with drugs. request a sample here

What is the forecast market size of the cardiovascular drugs market?

The cardiovascular drugs market forecast is expected to reach $107.77 billion in 2025 at a compound annual growth rate of 4%. request a sample here

How is the cardiovascular drugs market segmented?

The global cardiovascular drugs market is segmented -
1) By Type: Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic And Anti-Anginal Drugs)
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others
3) By Route Of Administration: Oral, Parenteral, Others
4) By Drug Classification: Branded Drugs, Generic Drugs
5) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs
request a sample here

Which region has largest share, and what is the market size and growth by geography according to the cardiovascular drugs global market report?

For more detail on this, request a sample here.

Who are the key players of the global cardiovascular drugs market?

Top competitors in the cardiovascular drugs market are Merck & Co, Sanofi S.A, Pfizer Inc, Bristol-Myers Squibb Company, Novartis AG. request a sample here.

What are the key trends in the global cardiovascular drugs market?

Major trends influencing the cardiovascular drugs market include acceptance of NOACs and replacing traditionally used anti-coagulants such as Warfarin and Heparin. request a sample here.

What are the major opportunities in the cardiovascular drugs market and the approaches companies can take to take advantage of them?

For detail on the future and current opportunities in the global cardiovascular drugs market, request a sample here.

How does the cardiovascular drugs market relate to the overall economy and other similar markets?